A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

NCT01952145 · Completed

Last updated 2026-05-28

This trial compared the effects of a combination of insulin degludec and liraglutide versus insulin glargine alone in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 557 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-09 · est. completion 2014-11

Where 91 sites · Argentina, Australia, Greece, Hungary, Mexico, Russia, Slovakia, South Africa, Spain, United States

What this study is testing ClinicalTrials.gov NCT01952145 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.

Treatments tested

insulin degludec/liraglutide Drug

Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
insulin glargine Drug

Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.

Main thing measured	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01952145 ↗